Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 2054-2058

  Donia, Ahmed F ^a   Gazareen, Sanaa H ^a   Ahmed, Hassan A ^a   Moustafa, Fatma E ^a   Shoeib, Ahmed A ^a   Ismail, Amani M ^a   Khamis, Said ^a   Sobh, Mohamed A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Children; Cyclophosphamide; Minimal change; Steroid dependent

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MESNA; PREDNISOLONE;

ADOLESCENT; AGE; ALOPECIA; ARTICLE; BODY SURFACE; BRONCHITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GONAD DYSFUNCTION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; SEX RATIO; URINARY TRACT INFECTION;

CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEPHROSIS, LIPOID; PREDNISOLONE; PROBABILITY; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; RECURRENCE; TREATMENT FAILURE;

EID: 0141507014     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg300     Document Type: Article

References (28)

1. Glassock RJ, Cohen AH, Adler SG. Primary glomerular diseases. In: Brenner BM, ed. The Kidney. WB Saunders, Philadelphia, PA, 1996; 1392-1497
2. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in nephrotic corticosteroid-dependent syndrome. Pediatr Nephrol 1997; 11: 415-417
3. Schnaper HW, Robson AM. Nephrotic syndrome: minimal change disease, focal glomerulosclerosis, and related disorders. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. Little Brown and Company, Boston, MA, 1997: 137-179
4. Trompeter RS. Minimal change nephrotic syndrome and cyclophosphamide. Archiv Dis Child 1986; 16: 727-729
5. Haubitz M, Ehlerding C, Kamino A, Koch KM, Brunkhorst R. Reduced gonadal toxicity after IV cyclophosphamide administration in patients with non malignant disease. Clin Nephrol 1988; 49: 19-23
6. Austin HA, Klippel JH, Balow JE, LeRiche NG, Steinberg AD. Therapy of lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619
7. Martin F, Lanwerys B, Lefbuze C, Devogelair JP, Houssian FA. Side effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-257
8. Cattran DC. Evidence-based recommendations for management of glomerulonephritis. Kidney Int 1999; 55: S1-S62
9. Gandhi R, Thomas C. Cyclophosphamide pulse therapy in frequently relapsing nephrotic syndrome. Nephron 1990; 55: 444
10. Jones BF. Cyclophosphamide pulse therapy in frequently relapsing nephrotic syndrome. Nephron 1993; 63: 472
11. Gulati S, Pokhariyal S, Sharma RK et al. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant 2001; 16: 2013-2017
12. Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Report of the International Study of Kidney Disease in Children. Lancet 1974; 2: 423
13. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration in estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571
14. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991; 337: 1555-1557
15. Broyer M, Meyrier A, Naudet P, Habib R. Minimal changes and focal segmental glomerular sclerosis. In: Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Wingearls CG, eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, UK, 1998; 492-535
16. Update on the 1987 task force report on high blood presssure in children and adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics 1996; 98: 649-658
17. Kaplan DW, Mammel KA. Adolescence. In: Hay WW Jr, Hayward AR, Levin MJ, Sandheimer JM, eds. Current Paediatric Diagnosis and Treatment. Appleton & Lang, CA, 1999; 102-145
18. Nephrotic syndrome in children. Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13: 159-165
19. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561-564
20. Primary nephrotic syndrome in children. Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20: 765-771
21. Srivastava RN, Agarwal RK, Chowdhary VP, Moudgil A, Bhuyan UN, Sunderram KL. Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependance. Int J Pediatr Nephrol 1987; 6: 245-250
22. Shohet I, Meyerovitch J, Aladjem M, Boichis H. Cyclophosphamide in treatment of minimal change nephrotic syndrome. Eur J Paediatr 1988; 147: 239-241
23. Garin EH, Pryor ND, Fennel RS, Richard GA. Pattern of response to prednisolone in idiopathic minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. Am J Dis Child 1998; 142: 985-988
24. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologic. Arch Dis Child 1987; 62: 1102-1106
25. Ueda N, Kuno K, Ito S. Eight and twelve week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child 1990; 65: 1147-1150
26. Kashtan C, Melvin T, Kim Y. Long term follow up of patients with steroid dependent minimal change nephrotic syndrome. Clin Nephrol 1988; 29: 79-85
27. Kemper M, Altrogge H, Ludwig K, Timmermann K, Müller-Wiefel D. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2000; 14: 772-775
28. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide - a new regime for steroid resistant minimal change nephrotic syndrome. Pediatr Nephrol 1994; 8: 1-3